BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Grasp Cancer - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://graspcancer.org
X-WR-CALDESC:Events for Grasp Cancer
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260612T140000
DTEND;TZID=America/New_York:20260612T153000
DTSTAMP:20260624T071555
CREATED:20260603T162845Z
LAST-MODIFIED:20260615T142932Z
UID:10000297-1781272800-1781278200@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 5C
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #1655: Who gets access? National discrepancies in clinical trial enrollment among patients with brain metastases. \nPoster #9533: Circulating tumor DNA (ctDNA) clearance after immune checkpoint inhibition (ICI) with radiotherapy (RT) as a prognostic indicator for patients with advanced melanoma. \n  \nTrack: Melanoma/Skin Cancers\, Care Delivery/Models of Care  |  Keywords: ctDNA\, Brain metastasis\, Clinical trials
URL:https://graspcancer.org/event/asco26-group5d/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260612T140000
DTEND;TZID=America/New_York:20260612T153000
DTSTAMP:20260624T071555
CREATED:20260528T112723Z
LAST-MODIFIED:20260615T142959Z
UID:10000293-1781272800-1781278200@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 5C
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #535: Adjuvant antibody-drug conjugate (ADC) eligibility and corresponding prognosis in HER2+ early breast cancer (eBC): A US-based real-world comparison of KATHERINE and DESTINY-Breast05 populations. \nPoster #TPS1147: A single-arm\, phase II study of sequential therapy with curative intent in de novo HER2+ metastatic breast cancer: The SAPPHO study. \n  \nTrack: Breast Cancer—Local/Regional/Adjuvant\, Metastatic |  Subtrack: Adjuvant Therapy\, Real-world outcomes\, HER2-Positive (HER2+) |  Keywords: HER2+\, ADC\, Trial in progress
URL:https://graspcancer.org/event/asco26-group5c/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260612T140000
DTEND;TZID=America/New_York:20260612T153000
DTSTAMP:20260624T071555
CREATED:20260528T111748Z
LAST-MODIFIED:20260615T143018Z
UID:10000292-1781272800-1781278200@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 5B
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #1055: Safety and efficacy of ZN-A-1041\, a highly blood-brain barrier (BBB)–permeable HER2 tyrosine kinase inhibitor (TKI)\, + trastuzumab deruxtecan (T-DXd) or pertuzumab-trastuzumab (PH) in HER2-positive metastatic breast cancer (HER2+ mBC): Phase Ic expansion results from the ZN-A-1041-101-US trial. \nPoster #1051: Real-world brain metastasis outcomes with T-DXd versus tucatinib-based therapy in second-line HER2-positive metastatic breast cancer. \n  \nTrack: Breast Cancer—Metastatic  |  Subtrack: HER2-Positive (HER2+) |  Keywords: Brain metastasis\, Trial in progress\, Real-world outcomes
URL:https://graspcancer.org/event/asco26-group5b/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260612T140000
DTEND;TZID=America/New_York:20260612T153000
DTSTAMP:20260624T071555
CREATED:20260517T213059Z
LAST-MODIFIED:20260615T151129Z
UID:10000267-1781272800-1781278200@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 5A
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #1141: Clinical impact and temporal evolution of mutational signatures in metastatic lobular breast cancer. \nPoster #TPS1166: IvoLoC: A phase II trial of ivonescimab (IVO) in endocrine-refractory hormone receptor (HR)–positive or triple-negative (TN) metastatic invasive lobular carcinoma (mILC). \n  \nTrack: Breast Cancer—Metastatic  |  Subtrack: Other Breast Cancer  |  Keywords: TNBC\, HR+\, ILC\, Trial in progress\, Treatment resistance
URL:https://graspcancer.org/event/asco26-group5a/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260612T100000
DTEND;TZID=America/New_York:20260612T113000
DTSTAMP:20260624T071555
CREATED:20260603T123322Z
LAST-MODIFIED:20260615T142748Z
UID:10000296-1781258400-1781263800@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 4D
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #4129: A phase I/II study of CDX-1140\, a CD40 agonist\, in combination with capecitabine and oxaliplatin (CAPOX) and pembrolizumab in subjects with biliary tract carcinoma: Phase 1 results. \nPoster #4109: Real-world treatment patterns and clinical outcomes among cholangiocarcinoma patients treated with futibatinib or pemigatinib \n  \nTrack: Gastrointestinal Cancer—Gastroesophageal\, Pancreatic\, and Hepatobiliary |  Subtrack: Hepatobiliary Cancer – Advanced/Metastatic Disease |  Keywords: Cholangiocarcinoma\, Immunotherapy\, Real-world outcomes\, Targeted therapy
URL:https://graspcancer.org/event/asco26-group4e/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260612T100000
DTEND;TZID=America/New_York:20260612T113000
DTSTAMP:20260624T071555
CREATED:20260528T110617Z
LAST-MODIFIED:20260615T142756Z
UID:10000291-1781258400-1781263800@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 4D
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #TPS1160: Phase III trial of brain MRI surveillance in stage IV breast cancer. \nPoster #1655: Who gets access? National discrepancies in clinical trial enrollment among patients with brain metastases. \n  \nTrack: Breast Cancer—Metastatic |  Subtrack: Outcomes/Quality\, HER2-Positive (HER2+) |  Keywords: Brain metastasis\, Trial in progress
URL:https://graspcancer.org/event/asco26-group4d/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260612T100000
DTEND;TZID=America/New_York:20260612T113000
DTSTAMP:20260624T071555
CREATED:20260528T110314Z
LAST-MODIFIED:20260615T142808Z
UID:10000290-1781258400-1781263800@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 4C
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #TPS643: Precision DC: Personalized neoantigen dendritic cell vaccine pilot trial for high-risk triple-negative breast cancer after neoadjuvant therapy. \nPoster #536: A randomized phase II trial of folate receptor alpha peptide vaccine in early-stage triple-negative breast cancer. \n  \nTrack: Breast Cancer—Local/Regional/Adjuvant  |  Subtrack: Adjuvant Therapy |  Keywords: TNBC\, Vaccine\, Trial in progress
URL:https://graspcancer.org/event/asco26-group4c/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260612T100000
DTEND;TZID=America/New_York:20260612T113000
DTSTAMP:20260624T071555
CREATED:20260528T105431Z
LAST-MODIFIED:20260615T142819Z
UID:10000289-1781258400-1781263800@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 4B
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #1093: Association of ESR1 amplification with survival and benefit from CDK4/6 inhibition in breast cancer. \nPoster #1079: Outcomes by lobular (lob) histology status at initial diagnosis in patients (pts) in the INAVO120 phase 3 trial with PIK3CA-mutated (mut)\, hormone receptor-positive (HR+)\, HER2-negative (HER2–)\, endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV). \n  \nTrack: Breast Cancer—Metastatic |  Subtrack: Hormone Receptor-Positive (HR+) |  Keywords: ESR1\, ILC\, PI3K\, Treatment resistance\, Trial in progress
URL:https://graspcancer.org/event/asco26-group4b/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260612T100000
DTEND;TZID=America/New_York:20260612T113000
DTSTAMP:20260624T071555
CREATED:20260517T212026Z
LAST-MODIFIED:20260615T142829Z
UID:10000266-1781258400-1781263800@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 4A
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #629: Real-world treatment patterns and mortality associated with GLP1-RAs in breast cancer patients. \nPoster #639: Impact of GLP1 receptor agonists on survival of breast cancer patients. \n  \nTrack: Breast Cancer—Local/Regional/Adjuvant  |  Subtrack: Outcomes/Quality |  Keywords: GLP1\, Real-world outcomes
URL:https://graspcancer.org/event/asco26-group4a/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260611T180000
DTEND;TZID=America/New_York:20260611T193000
DTSTAMP:20260624T071555
CREATED:20260528T105051Z
LAST-MODIFIED:20260615T142400Z
UID:10000288-1781200800-1781206200@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 3C
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #1571: National implementation of electronic patient-reported outcomes (ePROs) for remote symptom monitoring in oncology: The OncoPRO initiative. \nPoster #11061: Co-creating patient partnership within a national cancer trials network: Experience from Cancer Trials Ireland in partnership with the Irish Cancer Society. \n  \nTrack: Care Delivery/Models of Care\, Quality Care/Health Services Research |  Subtrack: Care Delivery/Models of Care/Implementation Science\, Health Services Research |  Keywords: PROs\, Symptoms\, Clinical trials
URL:https://graspcancer.org/event/asco26-group3c/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260611T180000
DTEND;TZID=America/New_York:20260611T193000
DTSTAMP:20260624T071555
CREATED:20260528T104638Z
LAST-MODIFIED:20260615T142412Z
UID:10000287-1781200800-1781206200@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 3B
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #TPS1158: Exploratory analysis of prognostic value of ctDNA monitoring among advanced breast cancer with oligometastatic disease: An ancillary biomarker study of JCOG 2110 (JCOG2110A1). \nPoster #11177: Prognostic value of circulating tumor DNA (ctDNA) for recurrence detection across solid tumors: A real-world meta-analysis. \n  \nTrack: Breast Cancer—Metastatic\, Quality Care/Health Services Research |  Subtrack: Non-Subtype-Specific Breast Cancer Therapies\, Real-world Data/Outcomes |  Keywords: ctDNA\, Oligometastasis
URL:https://graspcancer.org/event/asco26-group3b/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260611T180000
DTEND;TZID=America/New_York:20260611T193000
DTSTAMP:20260624T071555
CREATED:20260517T211027Z
LAST-MODIFIED:20260615T142714Z
UID:10000265-1781200800-1781206200@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 3A
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #1031: Concordance between circulating tumor DNA and tissue biopsy in patients with newly diagnosed recurrent breast cancer. \nPoster #TPS649: GEMINI-BREAST: Evaluating minimal residual disease (MRD) through longitudinal circulating tumor DNA (ctDNA) profiling in breast malignancies. \n  \nTrack: Breast Cancer—Metastatic\, Local/Regional/Adjuvant |  Subtrack: Biologic Correlates |  Keywords: ctDNA
URL:https://graspcancer.org/event/asco26-group3a/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260611T140000
DTEND;TZID=America/New_York:20260611T153000
DTSTAMP:20260624T071555
CREATED:20260601T171034Z
LAST-MODIFIED:20260615T142227Z
UID:10000294-1781186400-1781191800@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 2D
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #1522: Association of socioeconomic and clinical factors with overall survival in immunotherapy-eligible stage III non-small cell lung cancer following definitive chemoradiation. \nPoster #12044: A mediation analysis of neurocognitive deficits and patient-reported mood among patients with lung cancer with brain metastases. \n  \nTrack: Care Delivery/Models of Care\, Symptom Science and Palliative Care\, Lung Cancer
URL:https://graspcancer.org/event/asco26-group2e/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260611T140000
DTEND;TZID=America/New_York:20260611T153000
DTSTAMP:20260624T071555
CREATED:20260528T104343Z
LAST-MODIFIED:20260615T142251Z
UID:10000286-1781186400-1781191800@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 2D
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #1057: Real-world cardiotoxicity with HER2 antibody–drug conjugates and survival after treatment continuation. \nPoster #1034: Real-world outcomes and tumor gene expression analysis of sacituzumab govitecan (SG)- and trastuzumab deruxtecan (T-DXd)-treated metastatic breast cancer (MBC). \n  \nTrack: Breast Cancer—Metastatic  |  Subtrack: HER2-Positive (HER2+)\, Biologic Correlates |  Keywords: Real-world outcomes\, ADC\, HR+\, TNBC
URL:https://graspcancer.org/event/asco26-group2d/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260611T140000
DTEND;TZID=America/New_York:20260611T153000
DTSTAMP:20260624T071555
CREATED:20260528T103513Z
LAST-MODIFIED:20260615T142307Z
UID:10000285-1781186400-1781191800@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 2C
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #562: Predicting recurrence and survival in hormone receptor–positive (HR+)/HER2-negative (HER2–) early breast cancer (EBC) with machine learning models: Optimization of model complexity. \nPoster #566: Shared and distinct molecular signatures of resistance to different endocrine therapies (Alliance A011106). \n  \nTrack: Breast Cancer—Local/Regional/Adjuvant |  Subtrack: Biologic Correlates |  Keywords: HR+\, Treatment resistance
URL:https://graspcancer.org/event/asco26-group2c/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260611T140000
DTEND;TZID=America/New_York:20260611T153000
DTSTAMP:20260624T071555
CREATED:20260528T102235Z
LAST-MODIFIED:20260615T142318Z
UID:10000284-1781186400-1781191800@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 2B
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #1033: Rapid digital patient-derived organoid testing for guiding therapy in patients with metastatic breast cancer receiving antibody drug conjugates (ADCs). \nPoster #1023: Biology-informed predictive modeling and resistance monitoring in trastuzumab deruxtecan–treated metastatic breast cancer. \n  \nTrack: Breast Cancer—Metastatic  |  Subtrack: Biologic Correlates |  Keywords: ADC\, AI\, Treatment resistance
URL:https://graspcancer.org/event/asco26-group2b/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260611T140000
DTEND;TZID=America/New_York:20260611T153000
DTSTAMP:20260624T071555
CREATED:20260517T205718Z
LAST-MODIFIED:20260615T142334Z
UID:10000264-1781186400-1781191800@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 2A
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #1036: Prognostic impact of PIK3CA amplifications and co-occurring mutations detected through circulating tumor DNA (ctDNA) in metastatic breast cancer (MBC). \nPoster #TPS1148: ReDiscover-2\, a phase 3 study of zovegalisib (zovega\, RLY-2608) + fulvestrant (fulv) versus capivasertib (capi) + fulv as treatment for locally advanced or metastatic PIK3CA-mutant HR+/ HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor. \n  \nTrack: Breast Cancer—Metastatic  |  Subtrack: Biologic Correlates\, Hormone Receptor-Positive (HR+) |  Keywords: PI3K\, ctDNA\, Co-mutations\, Trial in progress
URL:https://graspcancer.org/event/asco26-group2a/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260611T100000
DTEND;TZID=America/New_York:20260611T113000
DTSTAMP:20260624T071555
CREATED:20260528T095426Z
LAST-MODIFIED:20260615T142159Z
UID:10000283-1781172000-1781177400@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 1B
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #1073: (RW) post-progression outcomes following first-line (1L) ribociclib (RIB) + aromatase inhibitor (AI) versus AI alone in African American and low socio-economic status (SES) patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) in US. \nPoster #1648: Survival outcomes with immune checkpoint inhibitors among patients with cancer from minoritized racial and ethnic groups: A systematic review and meta-analysis. \n  \nTrack: Breast Cancer—Metastatic\, Care Delivery/Models of Care |  Subtrack: Hormone Receptor-Positive (HR+)\, Discrepancies in Care |  Keywords: Real-world outcomes\, Racial disparities
URL:https://graspcancer.org/event/asco26-group1b/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260611T100000
DTEND;TZID=America/New_York:20260611T113000
DTSTAMP:20260624T071555
CREATED:20260526T205855Z
LAST-MODIFIED:20260615T142113Z
UID:10000282-1781172000-1781177400@graspcancer.org
SUMMARY:GRASP at ASCO26: Group 1A
DESCRIPTION:  \nThe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs. \n\nRegister Below\nThis ASCO26 Poster Walkthrough group will explore key findings from the following posters: \nPoster #1024: Organ- and histology-specific molecular and immune landscape of metastatic breast cancer. \nPoster #560: Prognostic value of an MRI-derived recurrence assay in women with hormone receptor–positive\, HER2-negative breast cancer: A retrospective\, multi-center analysis. \n  \nTrack: Breast Cancer—Metastatic\, Local/Regional/Adjuvant  |  Subtrack: Artificial Intelligence |  Keywords: AI\, HR+
URL:https://graspcancer.org/event/asco26-group1a/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/89557121854?pwd=YF6WGlhMWF507y7kUQn7tusaab8TfE.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T140000
DTEND;TZID=America/New_York:20251218T153000
DTSTAMP:20260624T071555
CREATED:20251125T183001Z
LAST-MODIFIED:20260409T151110Z
UID:10000223-1766066400-1766071800@graspcancer.org
SUMMARY:SABCS25 - Group 5E: HER2-negative Metastatic Breast Cancer; Brain Metastasis; Leptomeningeal Disease
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS5-03-01: Phase I Study of Stereotactic Radiation and Sacituzumab Govitecan with Zimberelimab in the Management of Metastatic Triple Negative Breast Cancer with Brain Metastases \nPoster #PS1-09-02: Intracranial activity of datopotamab deruxtecan (Dato-DXd) for patients with HER2-negative breast cancer and leptomeningeal disease (LMD): Results from Cohort C of the DATO-BASE phase 2 trial
URL:https://graspcancer.org/event/sabcs25-group5e/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/86051491979?pwd=jvD77adDH5FfDKRi4z6bBy7pfu2KvM.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T140000
DTEND;TZID=America/New_York:20251218T153000
DTSTAMP:20260624T071555
CREATED:20251125T182004Z
LAST-MODIFIED:20260409T151127Z
UID:10000222-1766066400-1766071800@graspcancer.org
SUMMARY:SABCS25 - Group 5D: HER2+ Locally Advanced and Metastatic Breast Cancer; Antibody-drug Conjugates; Treatment Resistance
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS5-12-23: Real-world outcomes of patients with HER2+ metastatic breast cancer after treatment with trastuzumab deruxtecan (T-DXd) in the United States \nPoster #PS5‑01‑16: Phase II Trial of the FASN Inhibitor\, Denifanstat (TVB‑2640)\, Plus Trastuzumab in Combination with Paclitaxel or Endocrine Therapy in Patients with HER2+ MBC Resistant to Trastuzumab
URL:https://graspcancer.org/event/sabcs25-group5d/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/86051491979?pwd=jvD77adDH5FfDKRi4z6bBy7pfu2KvM.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T140000
DTEND;TZID=America/New_York:20251218T153000
DTSTAMP:20260624T071555
CREATED:20251125T181004Z
LAST-MODIFIED:20260409T151140Z
UID:10000221-1766066400-1766071800@graspcancer.org
SUMMARY:SABCS25 - Group 5C: Metastatic Breast Cancer; Antibody-drug Conjugates; Treatment Response and Resistance
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \nPrefer a different time? These same posters will be discussed in another session. Click to join Group 4C instead. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS2-07-15: Immune biomarkers of standard-of-care chemoimmunotherapy response and resistance in real-world patient population: TBCRC061 \nPoster #PS4-02-23: Biomarkers of response and resistance to Sacituzumab Govitecan in HR+/HER2− advanced breast cancer: interim results from the phase II SOLTI ACROSS-TROP2 Trial
URL:https://graspcancer.org/event/sabcs25-group5c/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/86051491979?pwd=jvD77adDH5FfDKRi4z6bBy7pfu2KvM.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T140000
DTEND;TZID=America/New_York:20251218T153000
DTSTAMP:20260624T071555
CREATED:20251125T180505Z
LAST-MODIFIED:20260409T151226Z
UID:10000220-1766066400-1766071800@graspcancer.org
SUMMARY:SABCS25 - Group 5B: Metastatic Breast Cancer; Symptom Management; Dosing Strategies
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \nPrefer a different time? These same posters will be discussed in another session. Click to join Group 1F instead. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS2-03-17: Dose reductions in metastatic breast cancer patients: Frequency\, strategies\, and patient experience \nPoster #PS1-08-13: A retrospective study to assess real world rates of dose modification\, therapy discontinuation and treatment outcomes in patients receiving the oral CDK4/6 inhibitors Ribociclib and Palbociclib. \n 
URL:https://graspcancer.org/event/sabcs25-group5b/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/86051491979?pwd=jvD77adDH5FfDKRi4z6bBy7pfu2KvM.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T140000
DTEND;TZID=America/New_York:20251218T153000
DTSTAMP:20260624T071555
CREATED:20251125T180005Z
LAST-MODIFIED:20260409T151237Z
UID:10000192-1766066400-1766071800@graspcancer.org
SUMMARY:SABCS25 - Group 5A: Lobular Breast Cancer; Risk Prediction
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS3-11-06: Long-term prognostic and predictive value of lobular histology in the PALLAS trial \nPoster #PS3-07-21: Validation of the CTS5 as a predictor of late distant recurrence (DR) for HR+ HER2-negative Invasive Lobular Carcinoma (ILC)
URL:https://graspcancer.org/event/sabcs25-group5a/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/86051491979?pwd=jvD77adDH5FfDKRi4z6bBy7pfu2KvM.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T100000
DTEND;TZID=America/New_York:20251218T113000
DTSTAMP:20260624T071555
CREATED:20251125T162005Z
LAST-MODIFIED:20260409T150442Z
UID:10000219-1766052000-1766057400@graspcancer.org
SUMMARY:SABCS25 - Group 4E: HR+ Locally Advanced and Metastatic Breast Cancer; PIK3CA Mutations; Treatment Resistance
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \nPrefer a different time? These same posters will be discussed in another session. Click to join Group 3D instead. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS5-08-19: Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 plus fulvestrant in HR+HER2− advanced/metastatic breast cancer after progression on CDK4/6 inhibitor-based therapy \nPoster #PS5-08-25: ReDiscover-2\, a phase 3 study of RLY-2608 + fulvestrant versus capivasertib + fulvestrant as treatment for locally advanced or metastatic PIK3CA-mutant HR+/ HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor (trial in progress)
URL:https://graspcancer.org/event/sabcs25-group4e/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/86051491979?pwd=jvD77adDH5FfDKRi4z6bBy7pfu2KvM.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T100000
DTEND;TZID=America/New_York:20251218T113000
DTSTAMP:20260624T071555
CREATED:20251125T161506Z
LAST-MODIFIED:20260409T150451Z
UID:10000218-1766052000-1766057400@graspcancer.org
SUMMARY:SABCS25 - Group 4D: Triple Negative Locally Advanced and Metastatic Breast Cancer; Antibody-drug Conjugates; Immunotherapy
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS5-02-28: Safety analysis of phase 3 ASCENT-04 study of sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro for previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) \nPoster #PS5-08-18: Trofuse-011: a phase 3\, randomized\, open-label study of sacituzumab tirumotecan with or without pembrolizumab vs treatment of physician’s choice for previously untreated locally recurrent unresectable or metastatic triple-negative breast cancer
URL:https://graspcancer.org/event/sabcs25-group4d/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/86051491979?pwd=jvD77adDH5FfDKRi4z6bBy7pfu2KvM.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T100000
DTEND;TZID=America/New_York:20251218T113000
DTSTAMP:20260624T071555
CREATED:20251125T160506Z
LAST-MODIFIED:20260409T150808Z
UID:10000215-1766052000-1766057400@graspcancer.org
SUMMARY:SABCS25 - Group 4B: Metastatic Breast Cancer; Bone Metastasis
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS1-12-16: Chromatin Reader ZMYND8 Promotes Breast Cancer Bone Metastasis \nPoster #PS1-13-18: Single Intratumoral Drug Injection Yields Complete Response (CR) in Metastatic Breast Cancer (MBC) Bone Lesions: Results from a Phase 2a Trial
URL:https://graspcancer.org/event/sabcs25-group4b/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/86051491979?pwd=jvD77adDH5FfDKRi4z6bBy7pfu2KvM.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T100000
DTEND;TZID=America/New_York:20251218T113000
DTSTAMP:20260624T071555
CREATED:20251125T160007Z
LAST-MODIFIED:20260409T150818Z
UID:10000191-1766052000-1766057400@graspcancer.org
SUMMARY:SABCS25 - Group 4A: HER2+ and HER2-low Metastatic Breast Cancer; Antibody-drug Conjugates; Treatment Resistance
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \nPrefer a different time? These same posters will be discussed in another session. Click to join Group 3C instead. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS3-04-16: Decoding resistance to trastuzumab deruxtecan in metastatic breast cancer: S100P signaling and immune-niche barriers \nPoster #PS5-01-24: Evorpacept (ALX-148) combined with trastuzumab deruxtecan in patients with HER2 positive/HER2low metastatic breast cancer (mBC): results from the PRE-ISPY phase Ib trial
URL:https://graspcancer.org/event/sabcs25-group4a/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/86051491979?pwd=jvD77adDH5FfDKRi4z6bBy7pfu2KvM.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T180000
DTEND;TZID=America/New_York:20251217T193000
DTSTAMP:20260624T071555
CREATED:20251125T152008Z
LAST-MODIFIED:20260409T150308Z
UID:10000209-1765994400-1765999800@graspcancer.org
SUMMARY:SABCS25 - Group 3E: Metastatic Breast Cancer; Antibody-drug Conjugates; Treatment Resistance
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS5-08-07: Open-label Single-arm Phase 2 Trial of Trastuzumab Deruxtecan in Previously Treated HER2-Immunohistochemistry (IHC) 0 Advanced Breast Cancer – HER2 PARADIGM trial \nPoster #PS5-05-20: Real-world treatment patterns and outcomes in patients with HER2+ metastatic breast cancer after treatment with trastuzumab deruxtecan (T-DXd) in the US
URL:https://graspcancer.org/event/sabcs25-group3e/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/86051491979?pwd=jvD77adDH5FfDKRi4z6bBy7pfu2KvM.1
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T180000
DTEND;TZID=America/New_York:20251217T193000
DTSTAMP:20260624T071555
CREATED:20251125T151508Z
LAST-MODIFIED:20260409T150326Z
UID:10000208-1765994400-1765999800@graspcancer.org
SUMMARY:SABCS25 - Group 3D: HR+ Locally Advanced and Metastatic Breast Cancer; PIK3CA Mutations; Treatment Resistance
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \nPrefer a different time? These same posters will be discussed in another session. Click to join Group 4E instead. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS5-08-19: Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 plus fulvestrant in HR+HER2− advanced/metastatic breast cancer after progression on CDK4/6 inhibitor-based therapy \nPoster #PS5-08-25: ReDiscover-2\, a phase 3 study of RLY-2608 + fulvestrant versus capivasertib + fulvestrant as treatment for locally advanced or metastatic PIK3CA-mutant HR+/ HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor (trial in progress)
URL:https://graspcancer.org/event/sabcs25-group3d/
CATEGORIES:Poster Walkthrough
LOCATION:https://us02web.zoom.us/j/86051491979?pwd=jvD77adDH5FfDKRi4z6bBy7pfu2KvM.1
END:VEVENT
END:VCALENDAR